Skip to content

Edwards Lifesciences EW Payment for (Proceeds from) Other Investing Activity

Payment for (Proceeds from) Other Investing Activity at other companies

Abbott logo
AbbottABT
-$34M-467%
Boston Scientific logo
Boston ScientificBSX
-$48M-1,500%
LivaNova logo
LivaNovaLIVN
$290K+279%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$54M+80.0%
Medtronic logo
MedtronicMDT
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC

Other financials

Income statement

See full
Revenue$1.6B+16.7%
Gross profit$1.3B+15.7%
Operating income$477.6M+21.0%
Net income$380.7M+6.3%
EPS (diluted)$0.66+8.2%

Balance sheet

See full
Cash & equivalents$2.4B-22.3%
Total debt$702.9M+0.5%
Total equity$10.3B+2.0%
Total assets$13.3B+2.3%

Cash flow

See full
Operating cash flow$43.8M-84.4%
CapEx$64.9M+15.9%
Free cash flow-$21.1M-109%

Valuation

See full
Market cap$50.58B+10.5%
Enterprise value$48.83B+13.0%
P/E46.1×+35.1×
P/S0.0×

Profitability

See full
Gross margin77.9%-1.6pp
Operating margin21.4%-4.4pp
Net margin17.4%-58.3pp
FCF margin17.3%

Returns & leverage

See full
Return on equity10.7%-37.8pp
Debt / equity0.1×0.0×
Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForProceedsFromOtherInvestingActivities.

The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edwards Lifesciences's payment for (proceeds from) other investing activity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edwards Lifesciences's payment for (proceeds from) other investing activity?
Edwards Lifesciences (EW) reported payment for (proceeds from) other investing activity of $300K in Q1 2026.
How has Edwards Lifesciences's payment for (proceeds from) other investing activity changed year-over-year?
Edwards Lifesciences's payment for (proceeds from) other investing activity increased by 400.0% year-over-year, from -$100K to $300K.
What is the long-term trend for Edwards Lifesciences's payment for (proceeds from) other investing activity?
Over 3 years (2021 to 2025), Edwards Lifesciences's payment for (proceeds from) other investing activity has grown at a -43.8% compound annual growth rate (CAGR), from $44.4M to $7.9M.
What does payment for (proceeds from) other investing activity mean?
Net cash flows resulting from investing activities that do not fall under standard categories like securities or loans. This may include investments in joint ventures, real estate, or other non-financial assets. It serves as a catch-all for miscellaneous capital deployment or divestment activities.